

REMARKS

Claims 125-144 were pending in the present application. Applicants have amended claims 125-144. Support for these amendments can be found, *inter alia*, on page 2, lines 14-20 of the original specification. Applicants respectfully submit that the present Supplemental Amendment is fully supported by the original specification and does not raise any issue of new matter. Therefore, entry of the present Supplemental Amendment is respectfully requested. Upon entry of the present Supplemental Amendment, claims 125-144 will be under examination.

Applicants respectfully point out that the azithromycin in the claimed pharmaceutical dosage form is crystalline (emphasis added) azithromycin monohydrate hemi-ethanol solvate and such dosage form can be characterized in substantially the same way as the crystalline azithromycin monohydrate hemi-ethanol solvate.



CONCLUSION

In view of the claim amendments and the remarks, further and favorable considerations of the presently pending claims are respectfully requested.

It is believed that no fee is required in connection with the present Supplemental Amendment. However, if any fees are required, the Commissioner is authorized to charge such fees to our Deposit Account No. 16-1445.

Respectfully submitted,

Date: Aug. 16, 2005

lance liu

Customer No. 28523
Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 686-1652

Lance Y. Liu
Attorney for Applicant(s)
Reg. No. 45,379